Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.
Outcome
Prognosis
Tumor burden
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
26
02
2020
revised:
22
03
2020
accepted:
26
03
2020
pubmed:
4
5
2020
medline:
8
9
2021
entrez:
4
5
2020
Statut:
ppublish
Résumé
Previous reports have suggested that a higher bone marrow plasma-cell percentage (BMPC%) is associated with worse outcomes. However, it is unknown whether BMPC% is an independent predictor because genetic information was not available at that time. Currently the impact of BMPC% at diagnosis of multiple myeloma (MM) is not well described. We evaluated the prognostic impact of BMPC% ≥ 60% versus < 60% in 1426 newly diagnosed MM patients. All patients had an estimation of their BMPC% at diagnosis, and the highest percentage was used. Progression-free survival (PFS) and overall survival (OS) analyses were performed by the Kaplan-Meier method. Univariate and multivariate analyses for PFS and OS using the Cox proportional hazards model were performed for age, Revised International Staging System (R-ISS) score, creatinine level, and BMPC%. BMPC% ≥ 60% was found in 562 patients (39%), and the median PFS was shorter for these patients compared to BMPC% < 60% (22.6 vs. 32.1 months; P < .0001). Also, for OS, the median was shorter for the higher BMPC% group (53.4 vs. 75.4 months; P < .0001). On the multivariate analysis for PFS, age ≥ 65 years (hazard ratio [HR], 1.46; P < .0001), R-ISS (1-2 vs. 3) (HR, 0.49; P < .0001), and BMPC% ≥ 60% (HR, 1.23; P = .015) were predictive. On the multivariate analysis for OS, age ≥ 65 years (HR, 2.23; P < .001), R-ISS (1-2 vs. 3) (HR, 0.41; P < .0001), and BMPC% ≥ 60% (HR, 1.24; P = .02) were also predictive. BMPC% ≥ 60% at diagnosis is predictive for PFS and OS, even in a multivariate analysis that included known prognostic factors for MM.
Sections du résumé
BACKGROUND
Previous reports have suggested that a higher bone marrow plasma-cell percentage (BMPC%) is associated with worse outcomes. However, it is unknown whether BMPC% is an independent predictor because genetic information was not available at that time. Currently the impact of BMPC% at diagnosis of multiple myeloma (MM) is not well described.
PATIENTS AND METHODS
We evaluated the prognostic impact of BMPC% ≥ 60% versus < 60% in 1426 newly diagnosed MM patients. All patients had an estimation of their BMPC% at diagnosis, and the highest percentage was used. Progression-free survival (PFS) and overall survival (OS) analyses were performed by the Kaplan-Meier method. Univariate and multivariate analyses for PFS and OS using the Cox proportional hazards model were performed for age, Revised International Staging System (R-ISS) score, creatinine level, and BMPC%.
RESULTS
BMPC% ≥ 60% was found in 562 patients (39%), and the median PFS was shorter for these patients compared to BMPC% < 60% (22.6 vs. 32.1 months; P < .0001). Also, for OS, the median was shorter for the higher BMPC% group (53.4 vs. 75.4 months; P < .0001). On the multivariate analysis for PFS, age ≥ 65 years (hazard ratio [HR], 1.46; P < .0001), R-ISS (1-2 vs. 3) (HR, 0.49; P < .0001), and BMPC% ≥ 60% (HR, 1.23; P = .015) were predictive. On the multivariate analysis for OS, age ≥ 65 years (HR, 2.23; P < .001), R-ISS (1-2 vs. 3) (HR, 0.41; P < .0001), and BMPC% ≥ 60% (HR, 1.24; P = .02) were also predictive.
CONCLUSION
BMPC% ≥ 60% at diagnosis is predictive for PFS and OS, even in a multivariate analysis that included known prognostic factors for MM.
Identifiants
pubmed: 32360276
pii: S2152-2650(20)30161-0
doi: 10.1016/j.clml.2020.03.012
pmc: PMC7484262
mid: NIHMS1607580
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
596-601Subventions
Organisme : NCI NIH HHS
ID : P50 CA186781
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Am J Hematol. 2018 Aug 16;93(8):981-1114
pubmed: 30400719
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
Br J Haematol. 1983 Dec;55(4):683-90
pubmed: 6671088
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
Hematology. 2017 Sep;22(8):472-476
pubmed: 28463078
Br J Haematol. 1982 Jul;51(3):361-75
pubmed: 7104223
Clin Cancer Res. 2017 Apr 15;23(8):1981-1987
pubmed: 27698001
Cancer Chemother Rep 3. 1968 Dec;1(1):17-39
pubmed: 4195760
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Haematologica. 2014 Jan;99(1):163-71
pubmed: 23935020
Cancer. 2010 Jan 1;116(1):84-92
pubmed: 19862816
Cancer. 1991 Jun 15;67(12):3150-6
pubmed: 2044058
J Clin Oncol. 1989 Dec;7(12):1839-44
pubmed: 2585023
J Nucl Med. 2012 Dec;53(12):1829-35
pubmed: 23071351